Sno, its not the money for Kirk, its the time. Below is a special presentation which he advised, last minute, BAC he wanted to give. He doesnt like to do these and most of the time has others present. There will be some big news ziop/xon carT related. So, lets move on. There are plenty of other buyers here as price action couldnt be better.
Corporation (XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer, and Krish Krishnan, Chief Operating Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12th, at 8:40 a.m. Pacific Standard Time at Encore at the Wynn, Las Vegas, Nevada
At the end of 2013, tax selling forced an almost BK rgrx down to 5 cents. We are a 10 bagger from that level, and still, just as unknown and unfollowed. An amazing feat, by any standard of investing.
And still more amazing is the greater gains still are ahead. Until stock gathers a much bigger following and the mob arrives, stock will continue rewarding the very few here who know story.
We get news next week and all warrants will have to get exercised...imho
Very diffucult to buy stock today. This is how stock trades when short is not active with "fake" supply. New year high and another chart breakout. Next week warrant price and beyond/.................
And how about 98 year old Srybnik getting "gifted" 100,000 dollars? Are these guys nuts. I would think we could get the minutes and attendence records of the committees to see if payments to "non employee directors" justified payments. Maybe using the Freedom of Information Act.
Market in free fall, and stock closes higher after some profit taking yesterday?!. After huge gains this year, you would have expected more selling, but lots of bidders under this market.
When offer was .168, and that offer remains for 43k. So, must have been an AON for 100k. Getting interesting here.
If Ma has 1/2 a brain he will throw shareholders a bone at the sh meeting and announce another buyback if we are still under 20 cents by then. No talk from him will mean a thing; just action.
Last may, on a beautiful day, at the beautiful United nations Plaza, Ma had charts about stock price and compensation and a bunch of promises. The suite must have cost a bundle. But, Ma was running this dog and pony show. So, a year and many lies later, stock is 17 cents.
That is all the matters for a public company.
Now, vaso goes back to its home base with its tail between its legs. And shareholders?...................
If you held Ma to the same standard, he would have been fired long ago. My 600k was right on for 2012. And my message board standards, not deceptive at all. The point that he is overpaid cannot be denied by even the most heavy drinker of his Kool Aid.
And Hill's 700k. How about that? GEHC does no benefit to shareholder appreciation as it is perceived as transient. So, no need to overpay like that for a division that Ma should be running. What else is Ma doing for shareholders that keeps him away form vasohealthcare? Hill was brought on to ht Seimans on board. I guess that didnt work out, but what does here???
My 600k figure came from his 2012 compensation, which was 587k. His 2013 was 465k. And now 2014 was 369k. No apology or retraction to Ma or you. Maybe Ma could give shareholders an apology for share performance these last few years.....................
I got that from last years company docs. They must have not given him a bonus. Has he made more than shareholders the last 3 years. So, he is still overpayed. IMHO
But, you allegiance to this underperforming Ma is note worthy and just futhers the opinion that you are an employee of vaso. As such, posting here is not very wise. But, this is vaso, so dont have to worry about accountability........................
And, they even paid Srybnik 100,000 of shareholders dollars. For what? A special dividend? A payoff? This is the most egregious, unaccounted use of our money yet.
Hey, its just 100k, nobody will notice.
Not in NYC this year. That is good; its at the home base of vaso.
The proxy is insulting to shareholders in regard to compensation details. Ma's total compemsation in 2014 was 369,700.
Hill made an amazing 716k in 2014. Holy Cow!!! Nobody at a microcap company like vaso is worth that much. And he makes almost twice what the CEO makes.
And the totals for non employee directors working on committees is a real boondoggle. Castle made over 100k. And he determines others salaries at vaso. No conflict of interest there!. Leiberman and Movaseghi made 97k and 113k. I dont understand how these two guys, who are clearly director/employees are entitlted to any committee money. #$%$?
The Hill compensation is way over the top. Shareholders have lost their butts in the last 3 years and all of these guys are overpaid. Corrupt company Steals from shareholders.... that is the headline here. IMHO
They, as you say, already have most of the heart indications covered. So, why spend more on another very specific element for TB4 as it applies to the heart? The reason is pretty simple, they see how the market is valuing firms that are in early trials here and they think they will now be able to partner. Shorts and mm scammers can deny this all they want, but its just a matter of time. Shorts want to take it down, that is fine. The few that know the story should be happy to buy at a discount because as you say, one day we will wake up to a heart partner.........................Koreans might really want this, but rgrx is looking for a deep pocketed pharma to commit to expensive trials. So, get ALL patents needed..............
Seems to be much work in the heart area. RGN-352 has great potential, but no value to market cap at this time. As we have seen from amgn, cytk, qure, and cldn, this indication is worth 100's of millions. Can rgrx and Fink finally monitize RGN-352? Buy dry eye here, and get the heart indication for free?
Selloffs are just great places to add. Put bids out everday and buy all you can as the MM plays his games. In a year, it will be money in the bank. Best risk/reward out there. And still a very unknown company.